Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agile Therapeutics (AGRX)
OTHER OTC:AGRX
Agile Therapeutics (AGRX) Stock Price & Analysis
1,500 Followers
AGRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.20 - $3.40
Previous Close$1.42
Volume111.30K
Average Volume (3M)142.67K
Market Cap
$9.70M
Enterprise Value$7.46M
Total Cash (Recent Filing)$2.62M
Total Debt (Recent Filing)$378.00K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.65
Shares Outstanding6,856,229
10 Day Avg. Volume19,269
30 Day Avg. Volume142,667
Standard Deviation0.25
R-Squared0.07
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)0.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.39
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-1.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Agile Therapeutics News
PremiumCompany Announcements
Agile Therapeutics Merges with Insud Pharma Subsidiary
PremiumCompany Announcements
Agile Therapeutics Releases Updated Investor Presentation
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGRX FAQ
What was Agile Therapeutics’s price range in the past 12 months?
Agile Therapeutics lowest stock price was $0.20 and its highest was $3.40 in the past 12 months.
What is Agile Therapeutics’s market cap?
Currently, no data Available
When is Agile Therapeutics’s upcoming earnings report date?
Agile Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Agile Therapeutics’s earnings last quarter?
Agile Therapeutics released its earnings results on May 15, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.15.
Is Agile Therapeutics overvalued?
According to Wall Street analysts Agile Therapeutics’s price is currently Overvalued.
Does Agile Therapeutics pay dividends?
Agile Therapeutics does not currently pay dividends.
What is Agile Therapeutics’s EPS estimate?
Agile Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Agile Therapeutics have?
Agile Therapeutics has 6,856,229 shares outstanding.
What happened to Agile Therapeutics’s price movement after its last earnings report?
Agile Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Agile Therapeutics?
Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at N/A.
---
Agile Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 10.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.94%
Trailing 12-Months
Company Description
Agile Therapeutics
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
---
AGRX Company Deck
---
AGRX Earnings Call
Q4 2024
0:00 / 0:00
---
AGRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---